… patient. Following a US patent litigation with generics giant Teva … until January 30, 2027. BioMarin will also acquire the … Alongside these approved therapies, BioMarin will take ownership of the … employees. Moving into 2025, BioMarin has employed a strong …

… been a reset year for BioMarin Pharmaceutical, and as 2026 … the second acquisition made by BioMarin since the company enticed … year. BioMarin's play comes straight after patent litigation with … + Opfolda into new markets. BioMarin slashed staff in 2024 as …

… and June next year. BioMarin expects Amicus’ medicines to … that it has resolved patent litigation related to Galafold … is “fairly large” by BioMarin’s standards, and therefore represents … “overwhelmingly focused.” Given that BioMarin had become “one of the …

… , 11:47 AM EST) -- BioMarin Pharmaceutical Inc. has agreed to … by Amicus' settlement of patent litigation that secures U.S …

… licensed a set of patents that originated with Roche. … s exclusive use of the patents. Sandoz’ former owner, Novartis … have Amgen’s Enbrel patents invalidated, but lost in … which was originally developed by BioMarin Pharmaceutical and then Allievex, …

… infringe BioMarin's patent. The BioMarin patent was confirmed by the European Patent Office … of one of BioMarin's European patents, including BioMarin's expectations … the Unified Patent Court; and those factors detailed in BioMarin's …

Patent owner has chosen the EU court for the opening move in what promises to be a fierce battle with rival Ascendis Pharma Register for limited access Register to receive our newsletter and gain limited access to subscriber content. Register now Subscribe …

… Read: Rare Disease-Focused BioMarin Narrows Sales Focus, Cuts … type natriuretic peptide (CNP) patents. However, excluding this concern … upside and diversification beyond BioMarin's guidance. … increasing competitive pressure on BioMarin's key …

… AGV) superior to placebo. BioMarin Pharmaceutical Inc’s BMRN stock … TransCon CNP is comparable to BioMarin’s Voxzogo (vosoritide), … of infringing on BioMarin’s long-acting CNP patent portfolio, which … result in royalties to BioMarin.” The William Blair analyst …

… everyday needs become very difficult. BioMarin estimates the incidence of CLN2 … brain (cerebrospinal fluid) using BioMarin's patented technology. Brineura, the first … European Commission. Founded in 1997, BioMarin is a global biotechnology company …